Inhibitors of mitochondrial ROS, NLRP3 inflammasome, DNA sensor, cell death pathways and IL-1, including hydrogen sulfide, apocynin, mitochondrial-targeted antioxidants such as MitoQ and MitoTEMPO, mucolytic/antioxidant agents such as NAC, VX765, and iPS-MSCs mitochondrial transfer represent novel therapeutic options for treating oxidative stress-induced COPD. The gene discussed is NLRP3; the disease is chronic obstructive pulmonary disease.